FDA Approves Rocket Pharmaceuticals’ KRESLADI™ for Severe LAD-I in Children
Rocket Pharmaceuticals has received FDA approval for its gene therapy product KRESLADI
, aimed at treating severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients. This autologous hematopoietic stem cell-based therapy is specifically designed for children who have severe forms of LAD-I due to genetic variants in the ITGB2 gene and lack an HLA-matched sibling donor for transplantation. The approval is part of an accelerated pathway due to its potential to enhance neutrophil surface expressions.
About KRESLADI Approval
The FDA’s decision was influenced by early results demonstrating increases in important immune cell markers, namely CD18 and CD11a. As part of the approval process, Rocket Pharmaceuticals is tasked with verifying the therapy’s long-term clinical benefits through ongoing studies and registry data.
Key Facts About LAD-I
- Condition Overview: Severe LAD-I is a rare genetic disorder, where affected infants struggle with life-threatening infections.
- Incidence: In the U.S., LAD-I occurs in approximately 1 in 100,000 to 1 in 200,000 live births.
- Impact: Most patients suffer severe symptoms, leading to frequent hospitalizations and ineffective responses to conventional treatments.
Comments from Experts
Dr. Gaurav Shah, CEO of Rocket Pharmaceuticals, emphasized that this milestone reflects the collaborative efforts of families, researchers, and regulatory bodies in addressing this critical health issue. Dr. Donald Kohn, the principal investigator of the clinical study from UCLA, noted the profound impact of severe LAD-I on children and their families. He highlighted the years of research that led to the approval of KRESLADI.
Vanessa Tenembaum from the Jeffrey Modell Foundation also acknowledged the significance of the approval for patients and their families, underscoring the need for continued progress in treating primary immunodeficiencies.
Future Perspectives and Research
Following this approval, Rocket Pharmaceuticals plans to explore strategic avenues for monetizing the Rare Pediatric Disease Priority Review Voucher granted by the FDA. This initiative aims to facilitate further funding for research and enhance shareholder value.
Important Safety Information
Healthcare providers should monitor for potential complications linked to KRESLADI administration, including:
- Increased infection risk due to myeloablative conditioning.
- Potential for veno-occlusive disease and neutrophil engraftment failure.
- Risk of hypersensitivity reactions during treatment.
For further details regarding the clinical application and safety information of KRESLADI, potential users may visit the dedicated resource site or consult healthcare providers.
This breakthrough highlights Rocket Pharmaceuticals’ commitment to advancing genetic therapies for rare disorders, addressing significant unmet medical needs for vulnerable pediatric populations.
